Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Amortization - Intangibles (2016 - 2021)

ImmunityBio (IBRX) has disclosed Amortization - Intangibles for 7 consecutive years, with -$23000.0 as the latest value for Q2 2021.

  • On a quarterly basis, Amortization - Intangibles rose 52.08% to -$23000.0 in Q2 2021 year-over-year; TTM through Jun 2021 was -$836000.0, a 808.7% decrease, with the full-year FY2020 number at -$858000.0, down 28700.0% from a year prior.
  • Amortization - Intangibles was -$23000.0 for Q2 2021 at ImmunityBio, up from -$384000.0 in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $42000.0 in Q2 2019 to a low of -$572000.0 in Q1 2017.
  • A 5-year average of -$172823.5 and a median of -$81000.0 in 2018 define the central range for Amortization - Intangibles.
  • Peak YoY movement for Amortization - Intangibles: surged 133.33% in 2019, then plummeted 3100.0% in 2020.
  • ImmunityBio's Amortization - Intangibles stood at -$299000.0 in 2017, then soared by 72.91% to -$81000.0 in 2018, then soared by 85.19% to -$12000.0 in 2019, then tumbled by 3100.0% to -$384000.0 in 2020, then soared by 94.01% to -$23000.0 in 2021.
  • Per Business Quant, the three most recent readings for IBRX's Amortization - Intangibles are -$23000.0 (Q2 2021), -$384000.0 (Q4 2020), and -$381000.0 (Q3 2020).